Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial

Irvani, Seyed Sina Naghibi; Golmohammadi, Maryam; Pourhoseingholi, Mohamad Amin; Shokouhi, Shervin; Darazam, Ilad Alavi

doi:10.1186/s13063-020-04382-3

Cited by 24 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it should be noted that MS drugs are not particularly targeting the biology important to viral elimination (innate immune system) and do not influence the vascular pathology that is central to COVID-19 pathophysiology (Baker et al, 2020). Furthermore, some medications especially interferons have anti-viral effect and can attenuate the symptoms of COVID-19 in these patients (Irvani et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

Sahraian

Azimi

Navardi

et al. 2020

Multiple Sclerosis and Related Disorders

100

View full text Add to dashboard Cite

Background: COVID-19 is increasingly expanding all over the world. People who have an underlying disease or taking immunosuppressive drugs are generally more likely to be infected than the others. Multiple sclerosis (MS) patients may also be at risk of the disease and its complications depending on the medication they are taking. In this study, we evaluated a large population of patients with MS with different disease modifying drugs to show if any of them increases the risk. In addition, this study evaluates the incidence of COVID-19 in patients with MS, the rate of hospitalization or death in these patients. Method: This study was performed at the MS Clinic of Sina Hospital. All patients were contacted and their demographic characteristics were recorded. They were then asked about their COVID-19 symptoms. Patients with these symptoms were further evaluated. The documents were reviewed by treating neurologist and MS nurses to be sure about diagnosis of COVID19. The positive polymerase chain reaction (PCR) result or compatible lung computed tomography (CT) scan was acceptable for COVID-19 diagnosis. Results: 4647 patients answered the phone contact. Of these, 68 were infected with the COVID-19. The rate of hospitalization was 25% which is far more than general population. Two patients died from COVID-19. Rituximab was associated with increase rate of COVID-19 infection but not with hospitalization rate. There was no significant correlation between use of other drugs and rate of infection. Conclusion: This study revealed that the incidence of COVID-19 in MS patients is not more than general population, but the risk of hospitalization in these patients is higher than estimated for the disease. This highlights the importance of communicating to patients the severity of COVID-19 and the importance of risk reduction behaviors like social distancing and mask use.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

Sahraian

Azimi

Navardi

et al. 2020

Multiple Sclerosis and Related Disorders

100

View full text Add to dashboard Cite

show abstract

“…80 On this basis, a randomized controlled clinical trial to test the clinical efficacy and safety of the administration of IFN-b1 and IFN-b2 in moderate-to-severe COVID-19 patients has been designed (NCT04343768) ( Figure 2C, Table 1). 113 Targeting Th17 responses could offer another therapeutic strategy for treating severe COVID-19 patients, with a predominant Th17 immune profiles and complications associated with cytokine storm. 86,114 IL-17A can augment the release of proinflammatory cytokines by innate immune cells, including GM-CSF, IL-23, IL-1b and IL-6, and propagate lung pathology during ARDS, 115 and its blockade was beneficial in ameliorating lung inflammation in murine models 116 and myocarditis, 117 which is one of the major causes of high mortality rates in COVID-19 patients.…”

Section: Therapeutic Strategymentioning

confidence: 99%

T‐cell responses and therapies against SARS‐CoV‐2 infection

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2, a novel coronavirus strain. Some studies suggest that COVID‐19 could be an immune‐related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue damage, leading to worse disease outcomes. T cells can act as a double‐edge sword with both pro‐ and anti‐roles in the progression of COVID‐19. Thus, better understanding of their roles in immune responses to SARS‐CoV‐2 infection is crucial. T cells primarily react to the spike protein on the coronavirus to initiate antiviral immunity; however, T‐cell responses can be suboptimal, impaired or excessive in severe COVID‐19 patients. This review focuses on the multifaceted roles of T cells in COVID‐19 pathogenesis and rationalizes their significance in eliciting appropriate antiviral immune responses in COVID‐19 patients and unexposed individuals. In addition, we summarize the potential therapeutic approaches related to T cells to treat COVID‐19 patients. These include adoptive T‐cell therapies, vaccines activating T‐cell responses, recombinant cytokines, Th1 activators and Th17 blockers, and potential utilization of immune checkpoint inhibitors alone or in combination with anti‐inflammatory drugs to improve antiviral T‐cell responses against SARS‐CoV‐2.

show abstract

“…Inhibits viral entry and anti-inflammatory Rilinger et al [43] Perspective Tocilizumab Anti-inflammatory Sarma et al [44] Clinical trial Hydroxychloroquine Blocks viral infection Wilde et al [45] In vitro Cyclosporin A Inhibited coronavirus replication Abeygunasekera et al [46] Brief review Diethylcarbamazine Immune modulatory, enhances antibody production, antiviral activity Biembengut et al [47] In silico approach Coagulation modifiers Targeting SARS-CoV-2 main protease Mpro Irvani et al [48] Perspective Interferon Beta 1a, compared to Interferon Beta 1b Tan et al [49] In [56] Clinical trial Dexamethasone Anti-inflammatory the concentration of the antibodies given and may last for weeks or months. The effectiveness of the sera varies with the type of virus.…”

Section: Results: Convalescent Plasmamentioning

confidence: 99%

An updated review of potential therapeutic agents against COVID-19

Ahmad

Sohail

Chishti

2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease of 2019 (COVID-19) is a public health emergency of international concern caused by a novel coronavirus, i.e., Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Since it is a new virus, an effective remedy against the virus is yet unknown. SARS-CoV-2 is a member of order nidovirales, family coronaviridae. Previously known treatment strategies against Middle East Respiratory Syndrome and Severe Acute Respiratory Syndromes are being tested for their effectiveness against SARS-CoV-2. Thus, various clinical and observational studies aimed at identifying potential therapies against the disease. In our study, we reviewed various drugs along with their mechanism of action, including anti-virals, anti-bacterials, glucocorticoids, ACE inhibitors, anti retrovirals, antimalarials, monoclonal antibodies, plasma, and many more. Individual drugs are described and evaluated for their potential to treat SARS-CoV-2 infection. This study offers a brief review of the findings of trials conducted so far. Dexamethasone, convalescent plasma therapy, tocilizumab, remdesivir, and combination therapies are found to be beneficial against SARS-CoV-2.

show abstract

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial

Cited by 24 publications

References 0 publications

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

T‐cell responses and therapies against SARS‐CoV‐2 infection

An updated review of potential therapeutic agents against COVID-19

Contact Info

Product

Resources

About